Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The idiopathic thrombocytopenic purpura therapeutics market size is projected to be USD 693.23 million in 2025, USD 734.20 million in 2026, and reach USD 978.36 million by 2031, growing at a CAGR of 5.91% from 2026 to 2031. This report is segmented by Disease Duration (Newly Diagnosed and Others), Treatment Type (Corticosteroids, Others), Route of Administration (Oral, Others), Patient Age Group (Pediatric, Adult, Geriatric), Distribution Channel (Hospital, Retail, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Market Forecasts in Terms of Value (USD).

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Trends and Insights

Increasing Diagnosis of Persistent and Chronic ITP

Clinical underdiagnosis historically limited the apparent patient base for the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market. A French registry of 541 adults found that 46% were at least 65 years old at presentation, and 47% of that older group were at least 80 years old.China’s 2025 adult ITP guideline revised diagnostic and treatment guidance and reduced uncertainty around initial treatment eligibility. PMC.NCBI.NLM.NIH.GOV More consistent identification of patients can increase the number entering hematology care. Persistent and chronic disease creates continuing treatment needs after an initial diagnosis. Better hematology capacity in South Korea, India, and Australia is also bringing previously unrecognized cases into treatment pathways.

Shift Toward Targeted Steroid-Sparing Therapies

Corticosteroids remain a common first treatment, but durable remission after withdrawal occurred in only 20% to 40% of patients in the cited clinical evidence. Extended steroid use is also associated with hyperglycemia, osteoporosis, and cardiovascular events. This clinical gap supports the use of thrombopoietin receptor agonists and creates room for newer targeted therapies. In the LUNA 3 study, rilzabrutinib produced a durable platelet response in 23% of treated patients, compared with 0% for placebo. At 12 weeks, 64% of treated patients achieved a platelet response, and quality-of-life scores improved by 10.6 points compared with 2.3 points for placebo. These findings support earlier consideration of steroid-sparing treatment in appropriate patients.

High Annual Cost of Novel Therapies

Treatment cost is a central access constraint for the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market. Annual all-cause costs for treated chronic ITP patients averaged USD 34,293, compared with USD 8,895 for untreated patients. Direct ITP therapy costs averaged USD 8,838 per patient each year. The cited Italian analysis reported annual costs of EUR 11,397 (USD 12,328) for patients receiving high-dose or high-intensity corticosteroid regimens. Payers often require the use of corticosteroids, intravenous immunoglobulin, or generic immunosuppressants before authorizing newer options. Newly launched therapies also face scrutiny because long-term real-world evidence is limited.

Other drivers and restraints analyzed in the detailed report include:

• FcRn, BTK, SYK, and B-Cell Pathway Innovation
• Orphan-Disease Incentives and Specialty-Hematology Investment
• Variable Reimbursement and Prior Authorization

Segment Analysis

Chronic ITP held 47.60% of the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market share in 2025. This position reflects the need for long-term management after patients move beyond the newly diagnosed disease. Newly diagnosed ITP is often treated with short courses of corticosteroids and intravenous immunoglobulin. Persistent disease remains an important transition period between 3 and 12 months. Refractory or relapsed ITP is forecast to grow at an 8.10% CAGR through 2031. This group requires more intensive use of thrombopoietin receptor agonists, SYK inhibitors, and emerging biologics.

Rilzabrutinib was approved for adults with persistent or chronic ITP who had not responded sufficiently to previous treatment. The approval added an oral targeted choice for patients who previously had limited alternatives beyond splenectomy or off-label rituximab. Persistent ITP is gaining attention as a possible earlier treatment window. A 2025 Chinese real-world study reported an 89% initial response rate with first-line romiplostim plus low-dose dexamethasone in patients aged at least 60 years. The study reported stronger 6-month sustained remission than corticosteroid monotherapy. This evidence challenges the practice of delaying thrombopoietin receptor agonists until chronic disease.

Thrombopoietin receptor agonists held 38.90% of the treatment type share in 2025. Romiplostim, eltrombopag, and avatrombopag support this leading position. Corticosteroids retain a major role in newly diagnosed and acute presentations. Intravenous immunoglobulin and anti-D immunoglobulin remain relevant in rescue care and surgical preparation. Immunosuppressants and splenectomy have declined as targeted oral options have entered broader practice. The Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market size for targeted classes is growing as treatment choices diversify.

Monoclonal antibodies and targeted biologics are forecast to grow at an 11.40% CAGR through 2031. This class includes the BTK inhibitor rilzabrutinib and investigational intravenous efgartigimod. The ADVANCE NEXT Phase 3 study of intravenous efgartigimod began in October 2024 and has an expected completion in 2028. Gilead’s acquired gamgertamig is expected to move toward registrational studies from 2027. Fostamatinib and pipeline cevidoplenib offer a SYK-focused approach that differs from stimulating platelet production. This treatment diversity supports use in patients who do not respond to a single pathway.

Complete Report Scope:

• By Disease Duration and Phase
  • Newly Diagnosed ITP
  • Persistent ITP
  • Chronic ITP
  • Refractory/Relapsed ITP
• By Treatment Type
  • Corticosteroids
  • Intravenous Immunoglobulins (IVIG)
  • Anti-D Immunoglobulin
  • Thrombopoietin Receptor Agonists (TPO-RAs)
  • SYK Inhibitors
  • Monoclonal Antibodies & Targeted Biologics
  • Immunosuppressants
  • Splenectomy
  • Other Immunomodulatory Therapies
• By Route of Administration
  • Oral
  • Intravenous
  • Subcutaneous
  • Other Injectable Routes
• By Patient Age Group
  • Pediatric
  • Adult
  • Geriatric
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Specialty Pharmacies
  • Others
• By Geography
  • North America
    • United States
      • Canada
      • Mexico
  • Europe
    • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
  • Asia-Pacific
    • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
      • South Africa
      • Rest of Middle East and Africa
  • South America
    • Brazil
      • Argentina
      • Rest of South America

Geography Analysis

North America held 43.10% of the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market share in 2025. The United States benefits from academic hematology centers, specialty pricing, insurance coverage, and quick uptake after FDA approvals. Wayrilz launched in the United States through limited specialty pharmacies in September 2025. Canada is expanding public review activity for orphan hematology medicines. Mexico is improving diagnostic capture through urban tertiary hospital networks. Amgen, Novartis, Rigel, and Sanofi compete across overlapping later-line treatment settings in the region.

Europe held the second-largest regional position in 2025. Germany, the United Kingdom, France, Italy, and Spain each have different reimbursement systems. This creates uneven access to premium therapies across the region. The United Kingdom’s health technology assessment process and Germany’s AMNOG framework can limit use when direct comparative evidence is limited. Patient advocacy groups and investigator-led trial networks support treatment awareness and study participation. Orphan-drug designations and European regulatory reviews provide a pathway for new therapies, including rilzabrutinib.

Asia-Pacific is forecast to grow at a 9.30% CAGR through 2031. Japan approved avatrombopag for persistent and chronic ITP in August 2025, and Sanofi filed rilzabrutinib for Japanese marketing approval in October 2025. China’s 2025 guideline includes SYK and BTK inhibitors as subsequent treatment options. This supports domestic participants such as Jiangsu Hengrui’s hetrombopag and 3SBio’s recombinant TPO, while lowering barriers for international entrants. South Korea, India, and Australia add growth through wider hematology access and orphan-drug reviews. Middle East and Africa and South America remain smaller, although GCC tertiary centers and Brazilian patient registries support future therapy expansion.

List of Companies Covered in this Report:

• 3SBio Inc.
• Agios Pharmaceuticals
• Amgen
• Argenx SE
• Asahi Kasei
• Biotest
• Chugai Pharmaceutical
• CSL Behring
• Roche
• Genentech
• Grifols
• HUTCHMED Limited
• Immunovant, Inc.
• Jiangsu Hengrui Medicine Co., Ltd.
• KISSEI PHARMACEUTICAL
• Novartis
• Octapharma
• Oscotec Inc.
• Pfizer
• Rigel Pharmaceuticals, Inc.
• Sanofi
• Swedish Orphan Biovitrum
• Takeda Pharmaceuticals
• UCB
• Zenyaku Kogyo Co., Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support